- Home
- NCNA vs TCBP Comparison
NCNA vs TCBP Comparison
Compare NCNA & TCBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCNA
- TCBP
- Stock Information
- Founded
- NCNA 1997
- TCBP 2013
- Country
- NCNA United Kingdom
- TCBP United Kingdom
- Employees
- NCNA N/A
- TCBP N/A
- Industry
- NCNA Biotechnology: Pharmaceutical Preparations
- TCBP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NCNA Health Care
- TCBP Health Care
- Exchange
- NCNA Nasdaq
- TCBP Nasdaq
- Market Cap
- NCNA 4.3M
- TCBP 5.0M
- IPO Year
- NCNA 2017
- TCBP 2022
- Fundamental
- Price
- NCNA $1.14
- TCBP $0.38
- Analyst Decision
- NCNA Buy
- TCBP Strong Buy
- Analyst Count
- NCNA 2
- TCBP 1
- Target Price
- NCNA $25.00
- TCBP $2.40
- AVG Volume (30 Days)
- NCNA 238.3K
- TCBP 3.1M
- Earning Date
- NCNA 11-25-2024
- TCBP 11-25-2024
- Dividend Yield
- NCNA N/A
- TCBP N/A
- EPS Growth
- NCNA N/A
- TCBP N/A
- EPS
- NCNA N/A
- TCBP N/A
- Revenue
- NCNA N/A
- TCBP N/A
- Revenue This Year
- NCNA N/A
- TCBP N/A
- Revenue Next Year
- NCNA N/A
- TCBP N/A
- P/E Ratio
- NCNA N/A
- TCBP N/A
- Revenue Growth
- NCNA N/A
- TCBP N/A
- 52 Week Low
- NCNA $0.96
- TCBP $0.37
- 52 Week High
- NCNA $19.40
- TCBP $32.70
- Technical
- Relative Strength Index (RSI)
- NCNA 43.15
- TCBP 30.77
- Support Level
- NCNA $0.96
- TCBP $0.37
- Resistance Level
- NCNA $1.37
- TCBP $0.47
- Average True Range (ATR)
- NCNA 0.15
- TCBP 0.10
- MACD
- NCNA -0.00
- TCBP 0.01
- Stochastic Oscillator
- NCNA 26.09
- TCBP 2.65
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.
About TCBP TC BioPharm (Holdings) plc
TC BioPharm (Holdings) PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform. Harnessing the innate ability of GD-Ts has enabled the company to develop a range of clinical-stage cell therapies designed to combat cancer and viral infection.